Ligand Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2011	FY 2010
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '11 Jun 30, 2011	Jun '10 Jun 30, 2010
Net Income	-2.9	-2.76	-1.35	-0.95	0.07	-0.54
Depreciation & Amortization	1.56	1.56	0	-	-	-
Loss (Gain) on Equity Investments	-	-	-	-	-	0.1
Stock-Based Compensation	0.04	0.04	0.27	0.46	0.26	-
Other Operating Activities	0.01	-	-	-	-0.41	0.27
Change in Accounts Receivable	-0	-0	-0	-0.02	-0.03	-0.02
Change in Accounts Payable	0	0	-0.01	0.17	-0	-0
Change in Other Net Operating Assets	0.02	0.02	0.01	-	-0	0
Operating Cash Flow	-1.27	-1.14	-1.08	-0.34	-0.12	-0.19
Capital Expenditures	-3.4	-4.42	-2.86	-	-	-
Investment in Securities	-	-	-	-	-0.04	-0.15
Other Investing Activities	-0.36	-0.29	-	-	-	-
Investing Cash Flow	-3.76	-4.71	-2.86	-	-0.04	-0.15
Issuance of Common Stock	3.34	3.34	9	1.58	-	0.49
Other Financing Activities	-0.22	-0.22	-0.57	-	-	-
Financing Cash Flow	3.12	3.12	8.43	1.58	-	0.49
Foreign Exchange Rate Adjustments	0	0.01	-	-	-	-
Net Cash Flow	-1.91	-2.73	4.49	1.24	-0.16	0.15
Free Cash Flow	-4.67	-5.56	-3.94	-0.34	-0.12	-0.19
Free Cash Flow Margin	-	-	-	-	-147.87%	-198.37%
Free Cash Flow Per Share	-0.05	-0.06	-0.06	-0.04	-0.00	-
Levered Free Cash Flow	-3.81	-4.9	-3.51	-	-0.1	-
Unlevered Free Cash Flow	-3.81	-4.9	-3.51	-	-0.1	-
Change in Working Capital	0.02	0.02	-0.01	0.15	-0.03	-0.02

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.